First-of-its-kind patented privacy-preserving technology platform
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
IQVIA™
(NYSE: IQV) today announced the launch of a patented technology platform
that advances real-world research and protects genomic data privacy.
E360™ Genomics, a scalable, privacy-preserving genotypic-phenotypic
database solution, provides an efficient way to conduct genomic research
with genomic and clinical databases.
“Genomic data are critical to transforming clinical research and
healthcare delivery,” said Jon Resnick, president, Real-World &
Analytics Solutions at IQVIA. “This game-changing technology will be a
significant catalyst for scientific discovery, and improved patient
outcomes. It offers researchers more efficient and cost effective access
to genomic data while addressing privacy concerns.”
E360 Genomics platform enables life science customers immediate access
to aggregated data at scale to conduct a wide range of research
including association studies of genomics and observable traits,
comparative efficacy and safety trials, and burden-of-illness and
discovery analytics using non-identified data in a secure environment
that protects patients’ privacy. IQVIA’s patented techniques allow for
the removal of phenotypic, identifying information from genomic data
while retaining the critical linkage of clinical and genomics data to
improve research and healthcare delivery. The result is a more flexible
and less expensive approach for scientific inquiry into human biology,
drug discovery, and drug development.
Powered by IQVIA CORE™, the E360 Genomics platform can manage the scale
and complexity of genomic datasets and draw insights from a
significantly increased number of covariates while preserving privacy.
IQVIA CORE brings together a dynamic integration of unparalleled data,
transformative technology, advanced analytics and essential domain
expertise. IQVIA is committed to advancing global public health by
integrating data science and technology with human science expertise to
drive new discoveries and insights from increasingly large and complex
datasets.
Additional information about the E360 Genomics platform is available at E360™
Genomics.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics,
technology solutions and contract research services to the life sciences
industry. Formed through the merger of IMS Health and Quintiles, IQVIA
applies human data science — leveraging the analytic rigor and clarity
of data science to the ever-expanding scope of human science — to enable
companies to reimagine and develop new approaches to clinical
development and commercialization, speed innovation and accelerate
improvements in healthcare outcomes. Powered by the IQVIA CORE, IQVIA
delivers unique and actionable insights at the intersection of
large-scale analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 58,000
employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The
company uses a wide variety of privacy-enhancing technologies and
safeguards to protect individual privacy while generating and analyzing
information on a scale that helps healthcare stakeholders identify
disease patterns and correlate with the precise treatment path and
therapy needed for better outcomes. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical companies,
medical researchers, government agencies, payers and other healthcare
stakeholders tap into a deeper understanding of diseases, human
behaviors and scientific advances, in an effort to advance their path
toward cures. To learn more, visit www.iqvia.com.
IQVIAFIN
Click
here to subscribe to Mobile Alerts for IQVIA.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190305005262/en/
Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com)
+1.484.567.6732
Andrew
Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com)
+1.973.257.7144
Source: IQVIA